Abstract:Objective:To explore the feassibility to edit human p53 and PTEN,two tumor suppressor genes,by CRISPR-Cas9 technology and to evaluate the editing efficiency in vitro,and to provide the experimental study tools for transforming primary healthy cells into malignant tumor cells and establishment of humanized mouse models with human oncogenesis in vivo.Methods:The single-guide RNA(sgRNA)sequences were designed to target the common exon regions of p53 and PTEN mRNA isoforms based on software analysis,that could predict their gene editing efficiency.The sgRNAs with high scores were selected and cloned into Cas9-P2A-GFP plasmid to construct sgRNA-Cas9-P2A-GFP vector that co-expressed sgRNA,Cas9 and GFP.The 293T cells in logarithmic growth phase were transfected with the sgRNA-Cas9-P2A-GFP vector(experimental group)or PBS(control group)by Lipofectamine 2000.After two-week expansion,the GFP-positive 293T cells were purified by flow cytometric sorter,whose genomic DNA was extracted for further analysis.The DNA fragments containing the sgRNA targeting site were amplified from the extracted genomic DNA by PCR and purified by gel extraction.Then they were linked into the pEASY-Blunt Zero cloning vector and transformed into competent E.coli cells.The single colonies formed by pEASY-Blunt Zero vector transformed cells were used to extract the plasmid for DNA sequencing.And the sequencing results of control group and experimental group were compared to judge the gene editing efficiency.Results:Over 82% of the sgRNA-Cas9-P2A-GFP transfected cells were found to express GFP gene after flow sorting in experimental group,which was significantly higher than that of the pre-sorted cells(P<0.05).Genomic DNA was extracted from the sorted cells after expansion and used as PCR template.The length of the amplified fragments containing the p53 mutation site was 612 bp,while the lengths of the amplified fragments containing the PTEN-1/PTEN-2 mutation site were 667 and 947 bp.The results of sequencing showed that the efficiency of editing induced by p53-1,p53-2 and PTEN-2 sgRNA were 54.5%,45.5% and 33.3%,respectively. Conclusion:The sgRNAs p53-1,p53-2 and PTEN-2 designed for p53 and PTEN can successfully guide Cas9-mediated site-specific genome editing with high efficiency at the genome level.

CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response

p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

Potential high-frequency off-target mutagenesis induced by CRISPR/Cas9 in Arabidopsis and its prevention

CRISPR/Cas9 Gene Editing System Can Alter Gene Expression and Induce DNA Damage Accumulation

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Enhancing genome editing in hPSCs through dual inhibition of DNA damage response and repair pathways

Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response

Cell cycle arrest combined with CDK1 inhibition suppresses genome-wide mutations by activating alternative DNA repair genes during genome editing

Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing

Inhibition of 53BP1 Favors Homology-Dependent DNA Repair and Increases CRISPR–Cas9 Genome-Editing Efficiency

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?

Screening and efficiency verification of CRISPR-Cas9 single-guide RNA against human tumor suppressor gene p53 and PTEN

A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy

Altered DNA repair pathway engagement by engineered CRISPR-Cas9 nucleases

A high efficiency precision genome editing method with CRISPR in iPSCs

CRISPR–Cas9 Gene Editing Induced Complex On-Target Outcomes in Human Cells

A Targeted and Tuneable DNA Damage Tool Using CRISPR/Cas9

New advances in CRISPR/Cas-mediated precise gene-editing techniques

Frequent loss of heterozygosity in CRISPR-Cas9-edited early human embryos

DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 with improved proof-reading enhances homology-directed repair